New research indicates that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop traditional diet and exercise plans.
Findings released in a prominent health publication shows that while obese individuals often shed a large proportion of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications need to be cognizant of the potential of fast weight regain when the medication concludes," stated expert Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment weight within about one and a half years.
Comparing Approaches
The research, which reviewed dozens of studies involving thousands of participants, compared the effects of these new drugs with other pills.
Researchers note that individuals who shed pounds through lifestyle changes alone usually see a slower weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Nutrition scientists propose the mode of action of the drugs is key to understanding the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement results in appetite is uncontrolled, making binge eating a significant risk."
An Ongoing Disease?
Health authorities recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, due to the high risk of relapse, the treatment should be considered long-term.
This opinion is reinforced by drug manufacturers, who note that the results "underscore the persistent character of excess weight," similar to managing diseases like diabetes.
Patient Experiences
Users who have discontinued the jabs report a sudden return of cravings.
"I experienced something activating and I was suddenly ravenous," recalled one woman.
This challenge is exacerbated if patients have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Use
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Finally, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and long-term success likely depends on combined lifestyle support.
